Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A drug development perspective on targeting tumor-associated myeloid cells.

Majety M, Runza V, Lehmann C, Hoves S, Ries CH.

FEBS J. 2018 Feb;285(4):763-776. doi: 10.1111/febs.14277. Epub 2017 Oct 19. Review.

2.

Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model.

Kuen J, Darowski D, Kluge T, Majety M.

PLoS One. 2017 Jul 27;12(7):e0182039. doi: 10.1371/journal.pone.0182039. eCollection 2017.

3.

Fungal keratitis due to Schizophyllum commune: an emerging pathogenic fungus.

Reddy AK, Ashok R, Majety M, Chitta M, Narayen N.

Mycoses. 2016 Dec;59(12):757-759. doi: 10.1111/myc.12527. Epub 2016 Jul 12.

PMID:
27402206
4.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

5.

Fibroblasts Influence Survival and Therapeutic Response in a 3D Co-Culture Model.

Majety M, Pradel LP, Gies M, Ries CH.

PLoS One. 2015 Jun 8;10(6):e0127948. doi: 10.1371/journal.pone.0127948. eCollection 2015.

6.

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.

Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C.

Oncogene. 2013 Dec 12;32(50):5593-601. doi: 10.1038/onc.2013.245. Epub 2013 Jul 1.

7.

Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.

Sahin O, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, Mattern J, Schupp I, Chaouiya C, Thieffry D, Poustka A, Wiemann S, Beissbarth T, Arlt D.

BMC Syst Biol. 2009 Jan 1;3:1. doi: 10.1186/1752-0509-3-1.

8.

Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells.

Sauermann M, Sahin O, Sültmann H, Hahne F, Blaszkiewicz S, Majety M, Zatloukal K, Füzesi L, Poustka A, Wiemann S, Arlt D.

Oncogene. 2008 Feb 21;27(9):1320-6. Epub 2007 Aug 27.

PMID:
17724469
9.

High-throughput flow cytometry-based assay to identify apoptosis-inducing proteins.

Sauermann M, Hahne F, Schmidt C, Majety M, Rosenfelder H, Bechtel S, Huber W, Poustka A, Arlt D, Wiemann S.

J Biomol Screen. 2007 Jun;12(4):510-20. Epub 2007 May 3.

PMID:
17478479
10.

Statistical methods and software for the analysis of highthroughput reverse genetic assays using flow cytometry readouts.

Hahne F, Arlt D, Sauermann M, Majety M, Poustka A, Wiemann S, Huber W.

Genome Biol. 2006;7(8):R77. Epub 2006 Aug 17.

11.

Urokinase-type plasminogen activator induces proliferation in breast cancer cells.

Gandhari M, Arens N, Majety M, Dorn-Beineke A, Hildenbrand R.

Int J Oncol. 2006 Jun;28(6):1463-70.

PMID:
16685447
12.

Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle.

Arlt D, Huber W, Liebel U, Schmidt C, Majety M, Sauermann M, Rosenfelder H, Bechtel S, Mehrle A, Bannasch D, Schupp I, Seiler M, Simpson JC, Hahne F, Moosmayer P, Ruschhaupt M, Guilleaume B, Wellenreuther R, Pepperkok R, Sültmann H, Poustka A, Wiemann S.

Cancer Res. 2005 Sep 1;65(17):7733-42.

13.

Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1.

Lux A, Beil C, Majety M, Barron S, Gallione CJ, Kuhn HM, Berg JN, Kioschis P, Marchuk DA, Hafner M.

J Biol Chem. 2005 Mar 4;280(9):8482-93. Epub 2004 Dec 16.

Supplemental Content

Loading ...
Support Center